<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01867320</url>
  </required_header>
  <id_info>
    <org_study_id>130135</org_study_id>
    <secondary_id>13-N-0135</secondary_id>
    <nct_id>NCT01867320</nct_id>
  </id_info>
  <brief_title>Raltegravir for HAM/TSP</brief_title>
  <official_title>Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Human T-cell lymphotropic virus type 1 associated myelopathy/tropical spastic paraparesis
      (HAM/TSP) is an infection of the spinal cord. The infection is caused by a virus that has
      been known to cause cancers like leukemia and lymphoma. It causes a weakening of the legs.
      Researchers want to see if raltegravir, a drug for treating human immunodeficiency virus
      (HIV), can be used to treat HAM/TSP. They will see if the drug can reduce the amount of virus
      in the blood of people with HAM/TSP.

      Objectives:

      - To see if raltegravir can reduce the viral load of people with HAM/TSP.

      Eligibility:

      - Individuals at least 18 years of age who have HAM/TSP.

      Design:

        -  Participants will be screened with a physical exam and medical history. Blood samples
           will be collected. Imaging studies will be performed. A lumbar puncture will also be
           taken.

        -  Participants will take the study drug twice a day for 6 months. They will note each dose
           in a study diary, as well as any side effects.

        -  At the 6-month visit, participants will stop taking the study drug. They will have a
           physical exam and blood samples, as well as other tests.

        -  Participants will have two further exams 9 months and 15 months after starting the study
           drug. They will have a physical exam and blood samples, as well as other tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:

      In this pilot study, we wish to determine the effects of Raltegravir, a clinically approved
      HIV-1 integrase inhibitor, on HTLV-1 proviral load (PVL) in patients with HTLV-1 associated
      myelopathy / tropical spastic paraparesis (HAM/TSP). We will also provide safety and
      tolerability information on Raltegravir use in this condition and examine the correlation of
      immune activation markers in HAM/TSP with the effects of Raltegravir on the PVL.

      Study population:

      HAM/TSP, a relentlessly progressive and disabling myelopathy, occurs in up to 3% of HTLV-1
      infected subjects. It results from immune-mediated bystander damage of the neural tissues in
      association with an elevated PVL. In fact, a high PVL is considered to be the main risk
      factor for developing HAM/TSP as the risk of disease rises exponentially once the PVL exceeds
      1 %. Currently there is no effective treatment for HAM/TSP.

      There is evidence that active HTLV-1 replication, through the retroviral life cycle with new
      virus integration, is occurring in vivo and contributes to the total HTLV-1 PVL in infected
      subjects. Recently it was shown that Raltegravir could inhibit cell-free and cell-to-cell
      transmission of HTLV-1 in vitro. Given the substantial clinical experience with its use in
      HIV-1 infection and particularly its excellent safety profile, this agent is an attractive
      therapeutic option for patients with HAM/TSP, either alone or in combination with
      immunomodulatory treatment. In this pilot study we wish to determine the effects of
      Raltegravir in vivo on HTLV-1 PVL and immune activation markers in patients with HAM/TSP.

      Design:

      In this 15 months single center, single arm, open label, baseline versus treatment pilot
      clinical trial, sixteen subjects with HAM/TSP will receive Raltegravir at 400mg by mouth
      twice daily in an initial 6 months treatment phase, followed by an additional 9 months post
      treatment phase. Outcome measures will be collected every 3 months for the duration of the
      study.

      Outcome measures:

      The primary outcome measure is HTLV-1 proviral load, which will be measured by quantitative
      PCR. Secondary outcome measures include safety and tolerability of Raltegravir, which will be
      assessed by clinical exam and standardized neurological disability scales as well as clinical
      laboratory studies. In addition, viral and immunologic outcome measures investigating the
      impact of Raltegravir on HTLV-1 biology and its effects on immune function will be measured
      including HTLV-1 proviral load in different lymphocyte populations, the number of long
      terminal repeat (LTR) circles and HTLV-1 mRNA expression levels in freshly isolated PBMC,
      assays of spontaneous lymphoproliferation and T-cell phenotype analysis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 21, 2013</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of HTLV-1 Proviral load in HAM/TSP patients</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">19</enrollment>
  <condition>HTLV-I Infection</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  18 years or older

          -  Diagnosis of HAM/TSP as defined by WHO criteria, including a positive HTLV-1 EIA and
             confirmatory Western Blot.

          -  Patient must be willing and able to comply with all the aspects of trial design and
             follow-up.

          -  Patients must be able to provide informed consent

          -  If able to become pregnant or to father a child, agreeing to commit to the use of a
             reliable/accepted method of birth control (i.e. hormonal contraception (birth control
             pills, injected hormones, vaginal ring), intrauterine device, barrier methods with
             spermicide (diaphragm with spermicide, condom with spermicide) or surgical
             sterilization (hysterectomy, tubal ligation, or vasectomy) for the duration of
             treatment arm of the study

        EXCLUSION CRITERIA:

          -  Alternative diagnoses that can explain neurological disability

          -  Clinically significant medical disorders that, in the judgment of the investigators
             might expose the patient to undue risk of harm confound study outcomes or prevent the
             patient from completing the study. Examples of such conditions include but are not
             limited to poorly controlled cardiopulmonary conditions such as congestive heart
             failure, asthma or uncontrolled hypertension.

          -  Patient has received immunomodulatory/immunosuppressive therapy (including steroids)
             in the preceding 6 months.

          -  Patient with known myopathy or risk factors for CK elevation including being on other
             drugs known to cause myopathy or rhabdomyolysis.

          -  Pregnant or lactating women.

          -  Patient has received other investigational drugs within 6 months before enrollment

          -  Positive serological evidence of HIV, HTLV-II, Hepatitis B or C.

          -  Abnormal screening/baseline blood tests exceeding any of the limits defined below:

               -  Serum alanine transaminase (ALT) or aspartate transaminase (AST) levels greater
                  than 3 times the upper limit of normal values; total bilirubin &gt; 2.0mg/dl; Serum
                  amylase or lipase levels greater than twice the upper limit of normal values;
                  serum creatine phosphokinase (CK) level exceeding 3 xULN and confirmed on repeat
                  testing in 2 weeks.

               -  Platelet count &lt; 75,000/mm(3)

               -  Serum creatinine level &gt; 2.0 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Jacobson, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Neurological Disorders and Stroke (NINDS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-N-0135.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Ara√∫jo AQ, Andrade-Filho AS, Castro-Costa CM, Menna-Barreto M, Almeida SM. HTLV-I-associated myelopathy/tropical spastic paraparesis in Brazil: a nationwide survey. HAM/TSP Brazilian Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):536-41.</citation>
    <PMID>9859969</PMID>
  </reference>
  <reference>
    <citation>Asquith B, Hanon E, Taylor GP, Bangham CR. Is human T-cell lymphotropic virus type I really silent? Philos Trans R Soc Lond B Biol Sci. 2000 Aug 29;355(1400):1013-9. Review.</citation>
    <PMID>11186302</PMID>
  </reference>
  <reference>
    <citation>Aye MM, Matsuoka E, Moritoyo T, Umehara F, Suehara M, Hokezu Y, Yamanaka H, Isashiki Y, Osame M, Izumo S. Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol. 2000 Sep;100(3):245-52.</citation>
    <PMID>10965793</PMID>
  </reference>
  <verification_date>March 23, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HTLV-1</keyword>
  <keyword>HTLV-1 Associated Myelopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HTLV-I Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

